SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Dr. Andrés Rodríguez - 11 March, 2026 0

Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Dr. Juan Manuel Pérez - 10 March, 2026 0

Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Dr. Juan Manuel Pérez - 9 March, 2026 0

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad

Tag: COMPARE-ABSORB trial

Bioresorbable devices vs DES in patients at high risk of restenosis....

Últimas Noticias

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Noticias Institucionales

CHIP LATAM | Chapter 2 – Mexico: Complications Workshop

Fellow’s Corner 2026 – Submit Your Clinical Case

Watch Again: Cardiovascular Risk Factors in Women | SOLACI Technicians Webinar

Accesos